These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34412496)

  • 1. Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series.
    Chen Z; Hong X; Wang T; Guo Y; Huang C; Li M; He X; Ju W; Chen M
    Ann Palliat Med; 2021 Sep; 10(9):9354-9361. PubMed ID: 34412496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report.
    Pan Y; Hu J; Li T; Zhang S; Zhou W; Sun J; Wang J; Li W; Xu J
    Transpl Immunol; 2024 Aug; 85():102079. PubMed ID: 38964516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
    Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
    Front Immunol; 2021; 12():653437. PubMed ID: 34349755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang J; Huang H; Chen R; Lin Y; Ling Q
    Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
    De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
    Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and transplantation for hepatocellular carcinoma.
    Tabrizian P; Abdelrahim M; Schwartz M
    J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
    Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
    J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
    Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
    Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
    Mahn R; Vogt A; Kupczyk P; Sadeghlar F; van Beekum K; Hüneburg R; Meyer C; Toma M; Ahmadzadehfar H; Essler M; Matthaei H; Lingohr P; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
    Scand J Gastroenterol; 2020 Sep; 55(9):1057-1062. PubMed ID: 32692941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
    Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up Imaging After Liver Transplantation Should Take Into Consideration Primary Hepatocellular Carcinoma Characteristics.
    Dioguardi Burgio M; Ronot M; Fuks D; Dondero F; Cauchy F; Gaujoux S; Dokmak S; Paradis V; Durand F; Belghiti J; Vilgrain V
    Transplantation; 2015 Aug; 99(8):1613-8. PubMed ID: 25710611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
    World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study.
    Wang P; Li H; Shi B; Que W; Wang C; Fan J; Peng Z; Zhong L
    Oncotarget; 2016 Jun; 7(23):35071-83. PubMed ID: 27145461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
    Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
    Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab.
    Schnickel GT; Fabbri K; Hosseini M; Misel M; Berumen J; Parekh J; Mekeel K; Dehghan Y; Kono Y; Ajmera V
    Am J Transplant; 2022 Jun; 22(6):1699-1704. PubMed ID: 35080128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.